IQVIA and Flagship Pioneering Partner to Accelerate Breakthroughs in Life Sciences
Global clinical research and healthcare data leader IQVIA has announced a strategic collaboration with Flagship Pioneering, the venture firm behind transformative bioplatform companies, to fast-track the development of breakthrough therapies across the life sciences industry.
The partnership is designed to bolster Flagship’s ecosystem of biopharma startups by giving them access to IQVIA’s robust suite of resources, including advanced real-world data, analytics, AI-driven technologies, and deep expertise in clinical trial execution, drug development, and commercialization strategy.
The collaboration will focus on three core service areas:
- Drug development strategy and analytics
- Clinical development support
- Asset valuation and due diligence
Together, the organizations aim to create a more seamless and efficient pathway from discovery to commercialization for innovative therapies being developed by Flagship-backed companies.
“Working with Flagship Pioneering aligns with IQVIA’s mission to accelerate innovations for a healthier world,” said Rob Kotchie, President of Real World Solutions at IQVIA. “We’re excited to partner with a group known for bold thinking and next-generation science.”
David Khougazian, Executive Partner at Flagship Pioneering, added, “This collaboration brings enormous value to our platform companies, enabling them to expand their capabilities, accelerate progress, and ultimately bring impactful therapies to patients faster.”
The alliance combines Flagship’s pioneering bioplatform model with IQVIA’s scale and intelligence infrastructure, creating a powerful engine for life sciences innovation, value creation, and global impact.